LOS ANGELES, CA--(Marketwire - August 14, 2007) - Eugene Science, Inc. (OTCBB: EUSI), a developer and marketer of advanced nutraceutical products, today announced that a leading Japanese dairy company, Yotsuba Milk Products, has successfully launched a new line of heart-healthy yogurt using the Company's patented CZ™ ingredient.
With annual sales of approximately $770 million, Hokkaido, Japan-based Yotsuba is one of the largest dairy manufacturing companies in Japan, marketing and distributing their proprietary branded line of dairy products that includes milk, butter and cheese. Founded in 1967, and with 630 employees, Yotsuba products are widely advertised and distributed in most of the retail grocery and convenience stores throughout Japan.
With a population of 127 million and the world's third largest economy, the Japanese market holds tremendous potential for popular new products. Based on early reports from Yotsuba, Eugene Science expects to ship additional CZ™ to Yotsuba as sales grow and other products are envisioned.
"With a highly advanced awareness of the long-term and preventative health benefits, Japan is the world's top marketplace for functional food and nutraceuticals," said Seung Kwon Noh, Chief Executive Officer, Eugene Science. "Yotsuba is an excellent company with strong market reach for its 'CZ inside' labeled product which will serve to build consumer awareness and demand for other healthy cholesterol-lowering food and beverages."
About Eugene Science
Based in Bucheon, Kyunggi-Do, Korea, Eugene Science is a global biotechnology company tackling ailments such as heart disease, obesity and diabetes through innovation in the nutraceutical field. Its first commercial heart health product, CZ™, is a patented, nanoscience-based, water-soluble functional food ingredient containing natural plant sterols that help maintain healthy cholesterol levels by inhibiting its absorption. CZ™ is available in capsule form, or as a food or beverage additive. These plant sterols are approved by the U.S. FDA for health claims related to cholesterol-lowering efficacy. Please visit www.eugene21.com.
This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In addition, from time to time, Eugene Science, or its representatives, have made or may make forward-looking statements, orally or in writing. The words "estimate," "project," "potential," "intended," "expect," "anticipate," "believe" and similar expressions or words are intended to identify forward-looking statements. Such forward-looking statements may be included in, but are not limited to, various filings made by Eugene Science with the United States Securities and Exchange Commission (available at www.sec.gov), press releases or oral statements made with the approval of an authorized executive officer of Eugene Science. Actual results could differ materially from those projected or suggested in any forward-looking statements as a result of a wide variety of factors and conditions. Reference is hereby made to Eugene Science's Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 for information regarding those factors and conditions. Among the important factors that could cause actual results to differ materially from management's projections, estimates and expectations include, but are not limited to: changing economic influences in the nutraceutical industry; dependence on key personnel; actions of third parties; the market for nutraceutical products containing Eugene Science's CZ™ ingredient, and availability of adequate financing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only as of the date of this press release. Eugene Science undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.